Feasibility Clinical Trial Using the SPUR System to Demonstrate Safety and Efficacy.

Inclusion Criteria: * Patient is willing and able to provide informed consent and able to comply with the study protocol. * Peripheral arterial disease that can be treated using PTA. * Life expectancy \>1 year in the investigator's opinion * Male or non-pregnant female \> 18 years of age * Patent inflow artery * Target vessel(s) reconstitutes(s) at or above the ankle, excluding the dorsalis pedis and the calcaneal branch of the posterior tibial artery * Target lesion starts at or below 3 cm below the tibial plateau as measured by angiography * Target vessel for Spur device is ≥ 3.5 mm (4mm); ≥ 2.5 mm (3mm) in diameter by visual estimate. * Lesion(s) must be able to be treated with a minimum of one Spur or PTA or DCB product. * Infrapopliteal lesion(s) that are located in either the left or right leg Infrapopliteal artery(s) may be treated with only one modality per artery: DCB, Spur or Spur/DCB. * Arterial length/diameter and quantity must be able to be treated with DCB or Spur or Spur/DCB * The treated segment is defined as the total length of artery treated with PTA. * The cumulative treated segment of infrapopliteal artery(s) must be ≤34.0 cm. * Lesions in the treated segment may be continuous or may have gaps present between stenosis or occlusions * Patient has Rutherford Classification of 3-5. * Successful pre-dilatation of the target lesion. * Iliac, SFA and popliteal inflow lesions can be treated during the same procedure using standard angioplasty and/or approved device. These inflow lesions must be treated first, prior to consideration of treatment of infrapopliteal lesions. * The patient can be enrolled if the inflow lesions have acceptable angiographic results (must have \<30% residual stenosis and no evidence of embolization or flow limiting dissection) Exclusion Criteria: * Subject unwilling or unlikely to comply with the appropriate follow up time for the duration of the study * Prior stent(s) or bypass surgery within the target vessel(s) * Target lesion is located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion. * Previous treatment failure of inflow arteries (Iliac, SFA and popliteal) which required a surgical procedure. * Previous PTA of the target vessel within 30 day prior to index procedure * Angiographic evidence of thrombus within target limb. * Subject has an active infection of the foot, including pus or wet gangrene that is not controlled at the time of the procedure. * Planned major (above the ankle) amputation of the target limb * Recent MI or stroke \< 30 days prior to the index procedure. * Heart failure with Ejection Fraction \< 30% * Impaired renal function (GFR \<30 mL/min) and patients on dialysis * Subject with vasculitis, systemic Lupus Erythematosus or Polymyalgia Rheumatica. * Patient receiving systemic corticosteroid therapy. * Inability to tolerate concomitant antiplatelet and oral anticoagulation therapy. * Known allergies or sensitivities to heparin, aspirin (ASA), other anticoagulant therapies which could not be substituted, and/or paclitaxel or an allergy to contrast media that cannot be adequately pre-treated prior to the index procedure. * The patient is currently enrolled in another investigational device or drug trial that is interfering with the endpoints of this study.